ArticleInternational journal of nephrology and renovascular disease2012
High burden and unmet patient needs in chronic kidney disease.
Article in International journal of nephrology and renovascular disease, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design.PharmacoEconomics · 2019Pooled it
- Electronic Health Self-Management Interventions for Patients With Chronic Kidney Disease: Systematic Review of Quantitative and Qualitative Evidence.Journal of medical Internet research · 2019Pooled it
- Effects of uric acid-lowering therapy on the progression of chronic kidney disease: a systematic review and meta-analysis.Renal failure · 2018Pooled it
- Randomized clinical trial of the KH4L self-management program.Clinical kidney journal · 2026Article
- Public interest in chronic kidney disease and dialysis: a 20-year data analysis.Renal failure · 2025Article
- The role of socio-cultural-demographics in long-term haemodialysis survival.Bioinformation · 2025Article
- Drug-therapy-related problems and pharmacist interventions in the medical ward in northeast Ethiopia: focus on types, acceptability, and impacts.Frontiers in pharmacology · 2025Article
- Did stopping ultrasound surveillance during COVID-19 result in an increase of the dialysis access thrombosis rate?The journal of vascular access · 2024Article
- Unbiased kidney-centric molecular categorization of chronic kidney disease as a step towards precision medicine.Kidney international · 2024Article
- Income Level and Impaired Kidney Function Among Working Adults in Japan.JAMA health forum · 2024Article
- Artificial Intelligence in Kidney Disease: A Comprehensive Study and Directions for Future Research.Diagnostics (Basel, Switzerland) · 2024Review
- Tripled likelihood: polypharmacy increases the occurrence of drug therapy problems in hospitalized pediatric patients.Frontiers in pharmacology · 2024Article
- Qualitative assessment of the patient experience of primary hyperoxaluria type 1: an observational study.BMC nephrology · 2023Observational
- Health Care Resource Utilization and Related Costs of Patients With CKD From the United States: A Report From the DISCOVER CKD Retrospective Cohort.Kidney international reports · 2023Article
- Serum leptin levels in patients with chronic kidney disease and hypertensive heart disease: An observational cross-sectional study.Health science reports · 2023Article
- Treatment Adherence in CKD and Support From Health care Providers: A Qualitative Study.Kidney medicine · 2022 · on this mapArticle
- Evaluation of the Effect of Topiroxostat on Renal Function in Patients with Hyperuricemia: STOP-C Study, a Retrospective Observational Cohort Study.Drugs - real world outcomes · 2022Article
- Article
- Informed decision-making in delivery of dialysis: combining clinical outcomes with sustainability.Clinical kidney journal · 2021Review
- Association between serum uric acid and new onset and progression of chronic kidney disease in a Japanese general population: Iki epidemiological study of atherosclerosis and chronic kidney disease.Clinical and experimental nephrology · 2021Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) is a complex debilitating condition affecting more than 70 million people worldwide. With the increased prevalence in risk factors such as diabetes, hypertension, and cardiovascular disease in an aging population, CKD prevalence is also expected to increase. Increased awareness and understanding of the overall CKD burden by health care teams (patients, clinicians, and payers) is warranted so that overall care and treatment management may improve. This review of the burden of CKD summarizes available evidence of the clinical, humanistic, and economic burden of CKD and the current unmet need for new treatments and serves as a resource on the overall burden. Across countries, CKD prevalence varies considerably and is dependent upon patient characteristics. The prevalence of risk factors including diabetes, hypertension, cardiovascular disease, and congestive heart failure is noticeably higher in patients with lower estimated glomerular filtration rates (eGFRs) and results in highly complex CKD patient populations. As CKD severity worsens, there is a subsequent decline in patient health-related quality of life and an increased use of health care resources as well as burgeoning costs. With current treatment, nearly half of patients progress to unfavorable renal and cardiovascular outcomes. Although curative treatment that will arrest kidney deterioration is desired, innovative agents under investigation for CKD to slow kidney deterioration, such as atrasentan, bardoxolone methyl, and spherical carbon adsorbent, may offer patients healthier and more productive lives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.